Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Here is a more recent update on this apoAI/HDL infusion topic. ETC216/MDCO216 is dead. The AEGIS-II trial with CSL112 will be the first ever cardiovascular outcome study with an apoAI/HDL infusion intervention A chance to save the HDL hypothesis.
